Intracavitary chemotherapy for glioblastoma: present status and future directions.
Considerable efforts have been invested to improve local control of the glioma disease although its infiltrative nature leading to whole brain involvement is a fundamental characteristic and antagonistic to this endeavour. The typically local recurrence of glioblastoma in about 80% of the cases has prompted intracavitary treatments of which presently only a biodegradable wafer containing carmustine has shown statistically significant benefit regarding survival in three phase III trials. Based on that proof of principle, many new developments are attempting to improve on this concept, introducing different agents with otherwise high systemic toxicity and poor penetration. New pharmacological formulations offer longer sustained release, better adaptation to the geometry of the resection cavity, and allow repeated administration. Should local recurrence become effectively controlled, significant progress can be made to increase survival with very limited local and virtually no systemic side effects. Since all agents so far show only limited activity against solid tumor, complete resection seems to be the prerequisite for effective local therapies.